

MEETING ABSTRACT

Open Access

Alternative treatment option for high risk surgical candidates after previous cardiac surgery: The Scottish National TAVI Programme experience

Vincenzo Giordano^{1*}, Ashok Kar¹, Andrew Flapan², Neil Uren², Sai Prasad¹, Renzo Pessotto¹

From World Society of Cardiothoracic Surgeons 25th Anniversary Congress, Edinburgh Edinburgh, UK. 19-22 September 2015

Background/Introduction

Patients that require aortic valve replacement, having previously undergone cardiac surgery, have a higher morbidity and mortality with increased risks of mediastinal injury during re-operation.

Aims/Objectives

In the era of TAVI for high risk surgical candidates, we analysed our experience with redo conventional surgical aortic valve replacement (SAVR) and compared these results with those from patients who had undergone TAVI as a second heart operation.

Method

A retrospective, observational, comparative study was performed in the national centre offering TAVI. 149 consecutive patients underwent redo operation with SAVR (n = 59) or TAVI (n = 90) between October 2012 and February 2015. In the SAVR group patients with concomitant procedures (n = 8) or endocarditis (n = 8) were excluded from the analysis.

Results

Mean logistic Euroscore was 29.6 for redo-TAVI compared to 18.6 for redo-SAVR (p < 0.05). Type of previous cardiac surgery performed in each redo group is summarised in Table 1.

TAVI access was transfemoral (65.5%), transapical (6.7%), or trans-aortic (27.8%).

Despite a higher incidence of MACE (major adverse cardiac events) in SAVR patients, results indicated no significant differences between two groups in terms of

Table 1

Previous Cardiac Surgery	Redo-SAVR	Redo-TAVI
CABG	20	82
AVR	28	2
AVR + CABG	1	0
MVR	6	4
Congenital	4	0
Other Cardiac	0	2

all-cause and cardiovascular related mortality, stroke, myocardial infarction.

In details, hospital mortality was higher in SAVR group (5.1%) compared to TAVI group (2.2%), although it did not reach statistical significance.

There was a higher incidence of CVA in the SAVR versus TAVI group (6.8% vs. 2.2%; p = 0.385).

Patients were found to require permanent pacemaker insertion more often after TAVI (10% vs 3.4%; p = 0.2).

Finally, average length of post-operative hospital stay was significantly shorter in TAVI than SAVR group (5.4 vs 10.4 days; p < 0.00001).

Discussion/Conclusion

This retrospective analysis suggests that TAVI is preferable to SAVR in this high risk group of patients. Redo-SAVR remains a valid option for younger patients in whom long-term durability of the prosthetic valve is a concern.

Authors' details

¹Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK. ²Department of Cardiology Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK.

Full list of author information is available at the end of the article



¹Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, UK

Published: 16 December 2015

doi:10.1186/1749-8090-10-S1-A236

Cite this article as: Giordano et al.: Alternative treatment option for high risk surgical candidates after previous cardiac surgery: The Scottish National TAVI Programme experience. Journal of Cardiothoracic Surgery 2015 10(Suppl 1):A236.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

